Getting Started with the PARIS® Test
How to Order
For questions about ordering or patient eligibility, please contact Cure First’s clinical team by email at ParisTest@cure-first.org, or by phone: (425) 366-7614.
Cure First requires ideally 1 week advanced notice (minimum 48 hours) prior to a scheduled biopsy or procedure. This allows time for you/provider to receive a sample collection kit and instructions for best sample quality.
The PARIS® Test is private and secure and is available to patients in all U.S. states. The test is not currently covered by most insurance plans. While Cure First is a nonprofit organization, minimal costs apply.
Typical total cost: $5,000 if the sample is successfully tested
$2,500 non-refundable processing cost - This covers test customization, preparation, kit shipment, and coordination with your care team and is charged when your sample is shipped to the lab for testing.
$2,500 testing and report cost - This supports laboratory testing and delivery of results and is charged only if a CLIA-certified report can be provided to your physician.
$1,500 research report cost - This applies only if the sample does not pass quality checks but still yields important research findings that may be valuable for your case. This lower cost would be charged instead of the $2,500 testing and report cost noted above.
· Cure First also offers additional services that may be beneficial to you and your care team. Please download the brochure or ask us by calling (425) 366-7614.
What is the PARIS Test?
The PARIS Test is a clinical decision support tool designed to help physicians evaluate potential therapies for patients with any type of solid tumors (not blood cancers or lymphoma), particularly when standard treatment options are limited and their efficacy known to be poor. This avoids trial and error choices that waste precious time.
The test uses a live tumor biopsy from a patient’s cancer to evaluate how that individual’s tumor cells respond to a broad range of anti-cancer therapies outside the body, providing functional insight to inform treatment planning.
How the PARIS Test Works
The PARIS Test begins with a live tumor sample collected during a clinically indicated biopsy or surgical procedure. Once the sample arrives at Cure First's CLIA-certified laboratory, scientists generate patient-derived 3D tumor models.
These models are screened against a personalized panel of up to 47 anticancer agents including targeted agents, Antibody Drug Conjugates and chemotherapies. Using proprietary scoring metrics, the PARIS Test measures how active the drug are against your tumors and ranks them from the best to the least, including drugs that may have an exceptional response for you. DNA sequencing may indicate an actionable potential treatment in ~20% of cases; in contrast, the PARIS test by directly measuring drugs responses across at least 47 drugs has shown >90% actionability, indicating a potential drug with exceptional/good score across many tumor types.
How to Order
The PARIS Test may be ordered at least ideally a week and up to 48hrs before the procedureby the treating oncologist as part of the patient’s ongoing care. Cure First’s PARIS Test team of care coordinators and scientists supports the entire process, assisting with pre-screening, eligibility confirmation, and sample logistics.
Cure First’s scientific and clinical teams are available to support interpretation of PARIS® Test results and to consult directly with the treating physician, including participation in molecular tumor boards when appropriate.
Additional details on eligibility, sample requirements, and patient-facing materials are available in the resources section below.
Results and Interpretation
Test results are delivered directly to the treating oncologist in with an average turnaround of 3 weeks in a comprehensive, CLIA-compliant clinical report. The report ranks therapies based on tumor response and is intended to support physician-led clinical decision making.
Cure First's scientific team is available to:
Review and explain PARIS Test results with treating physicians
Consult directly with broader oncology care teams
Participate in molecular tumor boards to support interpretation and care planning
Resources and Support
Cure First operates the only laboratory in the United States with CLIA certification for a high-throughput, high-complexity functional drug response test across solid tumors, ensuring rigorous quality standards and data security.
Additional information is available below to support clinicians, patient navigators, and patients throughout the testing process.
Resources
Download a Brochure about the PARIS test